ライフサイエンスコーパス: BAT

1 BAT activity negatively correlated with arterial inflamm

2 BAT activity was negatively related to age, with a simil

3 BAT can also be used to monitor resolution of food aller

4 BAT displayed a significantly higher CDsens compared to

5 BAT dosing or sustained delivery may be optimal for pree

6 BAT identified 11 of 11 allergic patients, HR 10, and pa

7 BAT rapidly replenishes these stores by internalizing pr

8 BAT was ruxolitinib in 46 (89%) of 52 patients.

9 BAT, HR, and passive HR had a clinical sensitivity of 10

10 BAT, HR, and passive HR were performed on 11 peanut-alle

11 BAT, therefore, may reduce the number of OFC required fo

12 BAT-positive patients represent a group with a higher th

13 BATs to measure upregulation of basophil CD203c and indu

14 In 30 BAT-positive patients with 3 or more repeated scans, we

15 nerve activity (SNA, nadirs: -72 and -95%), BAT temperature (Tbat, -0.5 and -0.6 degrees C), expired

16 We calculated a BAT activity index (BFI) based on volume and intensity o

17 obesity; at 18 months, LP progeny displays a BAT activity comparable to control offspring and insulin

18 We attempted to establish a BAT protocol that would permit analysis of blood within

19 might be thermogenic lipokines that activate BAT in response to cold.

20 a higher than usual probability to activate BAT during a scan.

21 injection of 12,13-diHOME acutely activated BAT fuel uptake and enhanced cold tolerance, which resul

22 calculate the contribution of cold-activated BAT and WAT to daily DEE.

23 s with high and low levels of cold-activated BAT mass (high BAT, 96 +/- 37 g; low-BAT, 16 +/- 4 g).

24 ld stress condition to assess cold-activated BAT mass.

25 ance correlated with the extent of activated BAT in a given scan.

26 can enhance energy expenditure by activating BAT, and it has been shown to improve nutrient metabolis

27 In humans, active BAT can be visualized by (18)F-FDG uptake as detected by

28 Because only active BAT is detectable by (18)F-FDG uptake, these numbers und

29 h higher mean probability to redetect active BAT (52% +/- 25%) as compared with the overall prevalenc

30 tified 98 scans from 81 patients with active BAT.

31 Upon progression after BAT, men were rechallenged with oral enzalutamide 160 mg

32 ncreased as shown by immunoblot analysis and BAT.

33 ity in sIgE analyses, inhibition assays, and BAT.

34 316, 243 treatments, oxygen consumption, and BAT thermogenesis were diminished in UCP1 KO mice, but B

35 ant for regulation of energy expenditure and BAT activation, but not the metabolic response to cold.

36 city governs thermogenic gene expression and BAT function via mitochondria-nucleus communication, whi

37 ic SYK deletion in mice reduces BAT mass and BAT that developed consisted of SYK-expressing brown adi

38 ional interplay between skeletal muscle- and BAT-based thermogenesis under mild versus severe cold ad

39 t three-locus system in an F2 population and BAT is a computationally efficient and fast method for e

40 pairs along with the combination of SPT and BAT correctly distinguished allergic from tolerant patie

41 perating characteristic analysis for SPT and BAT was tree-nut dependent and yielded area under the cu

42 SPTs and BATs provided no additional information.

43 SPTs and BATs were negative in all patients tested.

44 at required for survival, a process known as BAT recruitment.

45 by the current standard method of assessing BAT-PET/CT-as it requires exposure to high doses of ioni

46 to capture by traditional CD63-/CD203c-based BAT.

47 Because BAT is a specialized metabolic tissue that takes up and

48 Thereafter, the relationship between BAT activity and CVD events was evaluated.

49 Both BAT and WAT undergo specific metabolic changes during ac

50 bolism was activated early (2 hours) in both BAT and the subcutaneous WAT depots, with the most strik

51 Our findings demonstrate that both BAT and muscle-based NST are equally recruited during mi

52 genesis were diminished in UCP1 KO mice, but BAT (18)F-FDG uptake was fully retained.

53 d to identify oleosin-sensitized patients by BAT.

54 stics analogous to those of both "classical" BAT and iBAT.

55 29 patients completed BAT and 21 proceeded to enzalutamide rechallenge, of who

56 g structure (TMGS) can achieve high-contrast BAT spectra covering the entire visible region.

57 ith and is co-activated by Prdm16 to control BAT-selective gene expression and mitochondrial biogenes

58 amma coactivator 1alpha (PGC1alpha) controls BAT-mediated thermogenesis by regulating the expression

59 acid homeostasis, associated with decreased BAT levels of retinoic acid in alcohol-consuming mice.

60 w that chronic alcohol consumption decreases BAT mass, with a resultant effect on thermoregulation.

61 UCP1-deficient BAT mitochondria exhibit reduced mitochondrial calcium b

62 During BAT, the only grade 3-4 adverse event occurring in more

63 e 3 or worse adverse events occurring during BAT in one [3%] patient each were pulmonary embolism, my

64 overactivation of cAMP/PKA signaling during BAT development ultimately causes apoptosis of brown adi

65 t-related deaths were reported during either BAT or enzalutamide retreatment.

66 We aimed to evaluate BAT in patients with metastatic castration-resistant pro

67 of anaesthetized rats decreased cold-evoked BAT sympathetic nerve activity (SNA, nadirs: -72 and -95

68 Delayed small bowel perforation following BAT is thought to occur secondary to mesenteric hematoma

69 of delayed small bowel perforation following BAT with extensive portomesenteric vein gas.

70 of delayed small bowel perforation following BAT without signs of intraabdominal injury on initial im

71 nti-IgE and tests were performed as follows: BAT-CD63 upregulation was assessed by flow cytometry; HR

72 urther confirmed as a specific biomarker for BAT imaging using [(18)F]-F-DPA, a TSPO-specific PET tra

73 d serve as a potential imaging biomarker for BAT.

74 en sensitivity, was significantly higher for BAT (80.1+/-17.4) compared to HR (23.4+/-10.31) and pass

75 PSA concentration from baseline (PSA50) for BAT (for all patients who received at least one dose) an

76 ed to define the potential clinical role for BAT in the management of metastatic castration-resistant

77 determine if somnogenic signals arising from BAT in response to beta3-AR stimulation are mediated by

78 1)C-HED RI, can predict levels of functional BAT.

79 nd binomial analysis of three-point gametes (BAT) for estimating gamete frequencies from F2 dominant

80 Subjects were divided into 2 groups (high BAT and low BAT) based on the presence of (18)F-FDG trac

81 low levels of cold-activated BAT mass (high BAT, 96 +/- 37 g; low-BAT, 16 +/- 4 g).

82 However, BAT protocols vary in blood anticoagulant used and tempe

83 Effective evaluation of human BAT stimulators is constrained by the current standard m

84 Together our findings identify BAT as a decisive physiological determinant of the onset

85 nt production of glucocorticoids that impair BAT functions.

86 Ad-GsKO mice had impaired BAT function, absent browning of WAT, and reduced lipoly

87 restriction partially restored the impaired BAT glucose uptake.

88 wn adipose tissue (BAT), leading to impaired BAT function and thermoregulation.

89 ity and metabolic syndrome through impairing BAT activity and WAT browning.

90 Mild but significant improved BAT tracer uptake was identified after calorie restricti

91 ilic gas xenon preferentially accumulates in BAT, leading to a radiodensity enhancement comparable to

92 ifies primed SEs of genes fully activated in BAT such as Ucp1.

93 Dose-response curves with the allergens in BAT allowed a differentiated individual dissection of re

94 also evident from structural alterations in BAT morphology, including mitochondrial architecture, in

95 fat diet-induced upregulation of TRIP-Br2 in BAT.

96 progesterone mediates a phenotypic change in BAT, which contributes to the gestational metabolic envi

97 s reveal a decreased triglyceride content in BAT, as well as impaired retinoic acid homeostasis, asso

98 mmune signaling and markers of cell death in BAT.

99 metabolic responses during cold exposure in BAT and WAT.

100 re greatly affected 4 hours post-exposure in BAT, while no polar metabolites were observed to signifi

101 ese mice exhibit elevated UCP1 expression in BAT and subcutaneous white adipose tissue, have increase

102 vation acutely reprograms gene expression in BAT toward a myogenic signature, including increased exp

103 Cx43 expression was higher in BAT compared to white adipose tissue.

104 We demonstrate a novel function of Id1 in BAT thermogenesis and programming of beige adipocytes in

105 NEOS into rRPa reversed the increase in BAT SNA evoked by blockade of GABA receptors in rRPa.

106 The increase in BAT SNA following mAChR blockade in rRPa does not depend

107 roduce 12,13-diHOME were uniquely induced in BAT by cold stimulation.

108 E-associated genes that could be involved in BAT functions.

109 n of diglyceride and monoglyceride levels in BAT.

110 ased the presence of damaged mitochondria in BAT.

111 Here, we show that cold activates mTORC1 in BAT, an effect that depends on the sympathetic nervous s

112 thermogenic genes program in WAT but not in BAT by promoting alternative activation of adipose macro

113 Interestingly, nonreleasers in HR but not in BAT had lower basophil count compared to releasers (249

114 enic genes, promoting a storage phenotype in BAT.

115 ment is mediated by a selective reduction in BAT vascular resistance, which greatly increases vascula

116 dipocytes through inflammation, resulting in BAT atrophy and increased overall adiposity in adult mic

117 inhibition of lipolysis and thermogenesis in BAT.

118 mpaired insulin-stimulated glucose uptake in BAT was confirmed in a rat model of type-2 diabetes.

119 In addition, cold-induced glucose uptake in BAT was positively related to glucose uptake in visceral

120 in increased cold-induced glucose uptake in BAT, as assessed by [(18)F]fluorodeoxyglucose positron e

121 Adrenergic stimulation can increase BAT (18)F-FDG uptake independently of UCP1 thermogenic f

122 taneous white adipose tissue, have increased BAT mass and higher energy expenditure.

123 e (SCOP), in the rRPa of warm rats increased BAT SNA (peak: +1087%), Tbat (+1.8 degrees C), Exp.

124 based on volume and intensity of individual BAT depots.

125 enhances, beta-adrenergic activation-induced BAT-specific gene expression in brown adipocytes.

126 l approach for counteracting obesity-induced BAT dysfunction.

127 tes a role for TRIP-Br2 in ER stress-induced BAT dysfunction, and inhibiting TRIP-Br2 could be a pote

128 uble factors capable of activating inducible BAT (iBAT) to combat obesity.

129 ify anthropometric parameters that influence BAT mass and activity and thus the potential efficacy of

130 ctive cholinergic input to the rRPa inhibits BAT SNA via activation of local mAChR.

131 INTERPRETATION: BAT is a safe therapy that resulted in responses in asym

132 Our findings indicate that the interscapular BAT of Ucp1 knockout mice exhibits mitochondrial disrupt

133 CL-316,243 were attenuated by 50% in intra-BAT capsaicin-treated mice.

134 ncreased sleep in mice and if this change is BAT dependent.

135 d Haemostasis Bleeding Assessment Tool (ISTH BAT) confirmed significant bleeding phenotypes in the ma

136 Likewise, BAT recognized 12 of 14 nonallergic subjects, HR 10, and

137 were divided into 2 groups (high BAT and low BAT) based on the presence of (18)F-FDG tracer uptake.

138 tivated BAT mass (high BAT, 96 +/- 37 g; low-BAT, 16 +/- 4 g).

139 e considered a suitable method for measuring BAT activation, especially in populations for whom PET/C

140 r overweight individuals have less metabolic BAT activity than the lean and young, but the role of th

141 ed to determine whether this lower metabolic BAT activity in older or overweight individuals can be e

142 At 10 months, BAT activity declines in LP progeny with the appearance

143 In mouse BAT, ablation of LRPPRC (LRP130), a potent regulator of

144 resolve after 1 year compared with negative BAT results (hazard ratio [HR], 2.33; 95% CI, 1.08-5.05)

145 ntenance, although it is required for normal BAT function and temperature homeostasis.

146 ological imaging suggested that the observed BAT contrast was due to (64)Cu-Dis binding to TSPO, whic

147 Surgical ablation of BAT prior to conception caused maternal and fetal hyperl

148 c innervation and cold-induced activation of BAT and WAT in lean young adults.

149 ent findings indicate that the activation of BAT via beta3-AR leads to increased sleep in mice and th

150 ions in rRPa produced similar activations of BAT during cold exposure, following a brain transection

151 hondrial integrity and metabolic activity of BAT.

152 ion are mediated by the sensory afferents of BAT, we tested the effects of CL-316,243 in mice with th

153 se numbers underestimate the total amount of BAT.

154 However, broad clinical application of BAT demands further standardization of the laboratory pr

155 which was confirmed by reduced expression of BAT markers in progesterone challenged oophorectomised m

156 enetic mechanisms regulating the function of BAT.

157 d 1.7% of ruxolitinib vs 0% (both grades) of BAT-treated patients.

158 The inhibition of BAT SNA mediated by mAChR in rRPa does not depend on act

159 es not mediate the cholinergic inhibition of BAT SNA.

160 ion in rRPa contributes to the inhibition of BAT sympathetic nerve activity (SNA) evoked by activatio

161 es require the intact sensory innervation of BAT.

162 ed from dynamic PET scans at the location of BAT and WAT.

163 genesis (NST) and can compensate for loss of BAT activity.

164 m and demonstrate the distinct metabolism of BAT during cold exposure.

165 etected a high amount of more than 300 mL of BAT tissue.

166 racticalities involved in the performance of BAT, we propose that it can be applied for selected case

167 hich greatly increases vascular perfusion of BAT.

168 in a dissociation of HDAC1 from promoters of BAT-specific genes, including uncoupling protein 1 (Ucp1

169 Here, we report quantification of BAT mass by xenon-enhanced computed tomography.

170 precise identification and quantification of BAT mass not only in lean, but also in obese, mouse phen

171 Obesity is associated with reduction of BAT function; however, it is not well understood how obe

172 sential role for mTORC1 in the regulation of BAT recruitment and metabolism in response to cold.

173 es to genetic and metabolic reprogramming of BAT.

174 We show that, during stimulation of BAT thermogenesis, the lipophilic gas xenon preferential

175 enoic acid (12,13-diHOME) is a stimulator of BAT activity, and that its levels are negatively correla

176 Adaptive thermogenesis of BAT was impaired in HFD offspring at weaning.

177 aimed to investigate glucose utilization of BAT by (18)F-FDG PET imaging.

178 analyses, as well as clinical validation of BAT as a diagnostic test for multiple target allergens a

179 The weight of BAT tissue and fat deposits were significantly increased

180 In adulthood, HFD offspring BAT had lower Ucp1 expression and thermogenic activity.

181 and ameliorated the impairment of offspring BAT due to maternal HFD.

182 iate the effect of AgRP neuron activation on BAT-myostatin expression and insulin sensitivity.

183 itherto uncharacterized effect of alcohol on BAT function, with possible implications for thermoregul

184 Alcohol's effect on BAT was assessed by histology, qPCR, HPLC, LC/MS and mea

185 sent evidence that the increased reliance on BAT-based NST depends on increased autonomic input, as i

186 expression, suggesting increased reliance on BAT-based thermogenesis.

187 e randomly assigned to pacritinib (n=220) or BAT (n=107).

188 open-label momelotinib 200 mg once a day or BAT (which could include ruxolitinib, chemotherapy, ster

189 , and 100% (0.4%) with -1 hour, -24 hour, or BAT dosing, respectively, and correlated significantly w

190 atients randomized to receive ruxolitinib or BAT, respectively.

191 Semiquantitative analysis of SPT or BAT and determining profilin-specific IgE can contribute

192 Our BAT method also had smaller variances in estimation of t

193 perature for 4 or 24 hours before performing BATs.

194 Positive BAT results (CD63 levels > 1.8%) were found in 58% of pa

195 The presence of certain biomarkers (positive BAT result and basophil count) may help to predict the l

196 Patients with positive BAT results (CD63 level >1.8%) were twice as likely to r

197 Moreover, in vitro data using primary BAT cultures show a direct impact of progesterone on exp

198 genic program, and inhibiting Hdac1 promotes BAT-specific gene expression through a coordinated contr

199 is not well understood how obesity promotes BAT dysfunction, especially at the molecular level.

200 or lack the necessary resolution to quantify BAT mass, especially in obese phenotypes, in which this

201 dy; 104 received momelotinib and 52 received BAT.

202 Patients received BAT, which consisted of intramuscular testosterone cipio

203 sis [n=1]); and four patients (8%) receiving BAT (lung adenocarcinoma [n=1], myelofibrosis [n=1], and

204 pocyte-specific SYK deletion in mice reduces BAT mass and BAT that developed consisted of SYK-express

205 )F-FDG PET identified intense inter-scapular BAT glucose uptake in all ZL control rats, while no foca

206 emical deafferentation of the intra-scapular BAT pads.

207 eters did not affect total or depot-specific BAT activity.

208 Still, BAT could diagnose subjects with low basophil number in

209 f the mTOR signalling pathway and subsequent BAT expansion.

210 Id1 suppresses BAT thermogenesis by binding to and suppressing PGC1alph

211 Surgical BAT ablation in 3-month-old LP offspring normalizes body

212 olic effectors under conditions of sustained BAT activation and highlight the relevance of cholestero

213 SUVmax, BAT volume, and SQUVmax were significantly different bet

214 se data imply an efficacy of drugs targeting BAT to treat metabolic disease that is at the same time

215 s were analyzed by basophil activation test (BAT) and CAP-FEIA-based cross- and self-inhibition tests

216 The basophil activation test (BAT) has emerged as having superior specificity and comp

217 ss-inhibition, and basophil activation test (BAT) in patients with yellow jacket or Polistes venom al

218 All had a basophil activation test (BAT) with moxifloxacin.

219 aimed at comparing basophil activation test (BAT), histamine release assay (HR), and passive sensitiz

220 as investigated by basophil activation test (BAT).

221 in vitro using the basophil activation test (BAT).

222 -nut solution and basophil activation tests (BAT) were performed.

223 Basophil activation tests (BATs) have promise for research and for clinical monitor

224 s) with IVIP, and basophil activation tests (BATs) in some patients.

225 oes not change upon BAT activation, and that BAT volume in mice can be measured by PET-CT with a radi

226 tly confirmed without OFC; in the cases that BAT is negative or the patient has non-responder basophi

227 We show that BAT phenotype is altered from day 5 of gestation, implic

228 We show that BAT phenotype is lost in murine pregnancy, while there i

229 The BAT inhibition test was the most reliable tool to confir

230 Combining the BAT with routine serologic testing allows classification

231 0% of ruxolitinib vs 0% (both grades) in the BAT arm, and grade 3 and 4 thrombocytopenia in 5.2% and

232 tinib group versus five (5%) patients in the BAT group (p=0.0003).

233 nib group and 40 (77%) of 52 patients in the BAT group completed the 24-week treatment phase.

234 90 patients in the BAT group crossed over to receive pacritinib at a median

235 omelotinib group and three (6%) of 52 in the BAT group had a reduction in the spleen volume by at lea

236 acritinib group and 14 (13%) patients in the BAT group throughout the duration of the study.

237 omelotinib group vs seven [14%] of 52 in the BAT group), thrombocytopenia (seven [7%] vs three [6%]),

238 n=3 [3%]), and hypotension (n=3 [3%]) in the BAT group.

239 which was grade 3) and in no patients in the BAT group.

240 otinib group and 12 (23%) of patients in the BAT group.

241 l integrity and upregulated autophagy in the BAT of Gja1 (adipoq) KO mice.

242 In the cases that the BAT is positive, food allergy is sufficiently confirmed

243 400 mg once daily or best available therapy (BAT) excluding JAK2 inhibitors until disease progression

244 JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or i

245 2 inhibitor, versus best available therapy (BAT) in patients with myelofibrosis who had suboptimal r

246 ne concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses.

247 Both brown adipose tissue (BAT) (i.e. uncoupling protein 1 (UCP1)-based) and skelet

248 Brown adipose tissue (BAT) activity, WAT browning and energy expenditure were

249 ociation with enhanced brown adipose tissue (BAT) activity.

250 Brown adipose tissue (BAT) and beige adipose tissue combust fuels for heat pro

251 oprotein processing in brown adipose tissue (BAT) and hepatic conversion of cholesterol to bile acids

252 lectively expressed in brown adipose tissue (BAT) and iWAT, and is translationally upregulated by bet

253 ve correlation between brown adipose tissue (BAT) and the degree of coronary atherosclerosis.

254 hod for PET imaging of brown adipose tissue (BAT) and translocator protein 18 kDa (TSPO) via a combin

255 phenotypes in classic brown adipose tissue (BAT) and white adipose tissue (WAT).

256 The discovery of brown adipose tissue (BAT) as a key regulator of energy expenditure has sparke

257 c6a2 in SAMs increases brown adipose tissue (BAT) content, causes browning of white fat, increases th

258 Due to uncoupling, brown adipose tissue (BAT) dissipates energy via heat generation, mitigating o

259 Recruitment of brown adipose tissue (BAT) has emerged as a potential tool to combat obesity a

260 t not in interscapular brown adipose tissue (BAT) in mice fed a high fat diet (HFD).

261 impaired activation of brown adipose tissue (BAT) in mice, their responses to cold environment remain

262 However, the role of brown adipose tissue (BAT) in regulating gestational metabolism is unknown.

263 In response to cold, brown adipose tissue (BAT) increases its metabolic rate and expands its mass t

264 ences thermogenesis of brown adipose tissue (BAT) independent of ambient temperature conditions.

265 nergy reservoir, while brown adipose tissue (BAT) is activated during cold exposure to generate heat

266 Brown adipose tissue (BAT) is an attractive therapeutic target to combat diabe

267 white adipose tissue, brown adipose tissue (BAT) is known to play critical roles for both basal and

268 Brown adipose tissue (BAT) is regulated by the sympathetic nervous system via

269 Brown adipose tissue (BAT) is specialized for energy expenditure, a process ca

270 and quantification of brown adipose tissue (BAT) mass remains a major challenge, as current tomograp

271 Brown adipose tissue (BAT) metabolism influences glucose homeostasis and metab

272 Brown adipose tissue (BAT) mitochondria exhibit high oxidative capacity and ab

273 Brown adipose tissue (BAT) provides a means of nonshivering thermogenesis.

274 pproaches to visualise brown adipose tissue (BAT) rely primarily on markers that reflect its metaboli

275 ly used to investigate brown adipose tissue (BAT) thermogenesis, which requires mitochondrial uncoupl

276 Brown adipose tissue (BAT) utilizes glucose and free fatty acids to produce he

277 the metabolic state of brown adipose tissue (BAT), due to its direct roles in thermogenesis, as well

278 noic acid signaling in brown adipose tissue (BAT), leading to impaired BAT function and thermoregulat

279 Brown adipose tissue (BAT)-induced thermogenesis is a promising therapeutic ta

280 ity of mitochondria in brown adipose tissue (BAT).

281 tes derived from mouse brown adipose tissue (BAT).

282 ogenesis (NST) besides brown adipose tissue (BAT).

283 ecific PD-L1 signal in brown adipose tissue (BAT).

284 ot induced in liver or brown adipose tissue (BAT).

285 lling thermogenesis of brown adipose tissue (BAT).

286 In contrast to BAT, cold stress reduces blood flow and (18)F-FDG uptake

287 n patients receiving ruxolitinib relative to BAT.

288 ruxolitinib, momelotinib was not superior to BAT for the reduction of spleen size by at least 35% com

289 scoring strategy, we determined a mean total BAT volume of 308 +/- 208 mL.

290 erforation following blunt abdominal trauma (BAT) is an uncommon situation with high morbidity and mo

291 activity, comorbidities, physical triggers, BAT results, complete blood cell count, C-reactive prote

292 ed on brown adipocytes, does not change upon BAT activation, and that BAT volume in mice can be measu

293 The inhibitory activity was determined using BAT inhibition and ELIFAB assay.

294 al muscle becomes the major site of NST when BAT activity is minimized.

295 It remains uncertain, however, whether BAT (18)F-FDG uptake is a reliable surrogate measure of

296 treated with ruxolitinib vs 23 (44.2%) with BAT (P = .40).

297 sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT.

298 binant allergen-based sIgE measurements with BAT represents a practicable way to diagnose clinically

299 Further studies with BAT are needed to define the potential clinical role for

300 d 30 eligible patients and treated them with BAT.